108 related articles for article (PubMed ID: 15781652)
21. Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7.
Bremer E; Samplonius DF; Peipp M; van Genne L; Kroesen BJ; Fey GH; Gramatzki M; de Leij LF; Helfrich W
Cancer Res; 2005 Apr; 65(8):3380-8. PubMed ID: 15833872
[TBL] [Abstract][Full Text] [Related]
22. Integration of monoclonal antibodies and immunoconjugates into the treatment of acute myeloid leukemia.
Amadori S; Stasi R
Curr Opin Hematol; 2008 Mar; 15(2):95-100. PubMed ID: 18300754
[TBL] [Abstract][Full Text] [Related]
23. Selective killing of cancer cells by peptide-targeted delivery of an anti-microbial peptide.
Sioud M; Mobergslien A
Biochem Pharmacol; 2012 Nov; 84(9):1123-32. PubMed ID: 22922046
[TBL] [Abstract][Full Text] [Related]
24. The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
Flavell DJ; Warnes SL; Bryson CJ; Field SA; Noss AL; Packham G; Flavell SU
Br J Haematol; 2006 Jul; 134(2):157-70. PubMed ID: 16771848
[TBL] [Abstract][Full Text] [Related]
25. Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells.
Yu B; Mao Y; Yuan Y; Yue C; Wang X; Mo X; Jarjoura D; Paulaitis ME; Lee RJ; Byrd JC; Lee LJ; Muthusamy N
Biomaterials; 2013 Aug; 34(26):6185-93. PubMed ID: 23726226
[TBL] [Abstract][Full Text] [Related]
26. Antitumor activity of a monoclonal antibody against CD47 in xenograft models of human leukemia.
Uno S; Kinoshita Y; Azuma Y; Tsunenari T; Yoshimura Y; Iida S; Kikuchi Y; Yamada-Okabe H; Fukushima N
Oncol Rep; 2007 May; 17(5):1189-94. PubMed ID: 17390064
[TBL] [Abstract][Full Text] [Related]
27. Screening microarrays of novel monoclonal antibodies for binding to T-, B- and myeloid leukaemia cells.
Belov L; Huang P; Chrisp JS; Mulligan SP; Christopherson RI
J Immunol Methods; 2005 Oct; 305(1):10-9. PubMed ID: 16125720
[TBL] [Abstract][Full Text] [Related]
28. A study of CD33 (SIGLEC-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing.
Hernández-Caselles T; Martínez-Esparza M; Pérez-Oliva AB; Quintanilla-Cecconi AM; García-Alonso A; Alvarez-López DM; García-Peñarrubia P
J Leukoc Biol; 2006 Jan; 79(1):46-58. PubMed ID: 16380601
[TBL] [Abstract][Full Text] [Related]
29. [Targeted killing of the Nalm-6 cells with 2E8-Genistein immunotoxin and its mechanism].
Chen YH; Tang YM; Shen HQ; Song H; Yang SL; Shi SW; Qian BQ; Xu WQ; Ning BT
Zhonghua Er Ke Za Zhi; 2009 Jan; 47(1):57-61. PubMed ID: 19573385
[TBL] [Abstract][Full Text] [Related]
30. Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates.
FitzGerald DJ; Wayne AS; Kreitman RJ; Pastan I
Cancer Res; 2011 Oct; 71(20):6300-9. PubMed ID: 21998010
[TBL] [Abstract][Full Text] [Related]
31. Anti-CCR7 monoclonal antibodies as a novel tool for the treatment of chronic lymphocyte leukemia.
Alfonso-Pérez M; López-Giral S; Quintana NE; Loscertales J; Martín-Jiménez P; Muñoz C
J Leukoc Biol; 2006 Jun; 79(6):1157-65. PubMed ID: 16603585
[TBL] [Abstract][Full Text] [Related]
32. Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum.
Lefebvre ML; Krause SW; Salcedo M; Nardin A
J Immunother; 2006; 29(4):388-97. PubMed ID: 16799334
[TBL] [Abstract][Full Text] [Related]
33. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv.
Cheng WW; Allen TM
J Control Release; 2008 Feb; 126(1):50-8. PubMed ID: 18068849
[TBL] [Abstract][Full Text] [Related]
34. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
Wu L; Adams M; Carter T; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB
Clin Cancer Res; 2008 Jul; 14(14):4650-7. PubMed ID: 18628480
[TBL] [Abstract][Full Text] [Related]
35. Combining adoptive cellular and immunocytokine therapies to improve treatment of B-lineage malignancy.
Singh H; Serrano LM; Pfeiffer T; Olivares S; McNamara G; Smith DD; Al-Kadhimi Z; Forman SJ; Gillies SD; Jensen MC; Colcher D; Raubitschek A; Cooper LJ
Cancer Res; 2007 Mar; 67(6):2872-80. PubMed ID: 17363611
[TBL] [Abstract][Full Text] [Related]
36. Active antiviral T-lymphocyte response can be redirected against tumor cells by antitumor antibody x MHC/viral peptide conjugates.
Cesson V; Stirnemann K; Robert B; Luescher I; Filleron T; Corradin G; Mach JP; Donda A
Clin Cancer Res; 2006 Dec; 12(24):7422-30. PubMed ID: 17189415
[TBL] [Abstract][Full Text] [Related]
37. Resistance of myeloid leukaemia cell lines to ricin A-chain immunotoxins.
Engert A; Brown A; Thorpe P
Leuk Res; 1991; 15(11):1079-86. PubMed ID: 1961012
[TBL] [Abstract][Full Text] [Related]
38. Different levels of CD52 antigen expression evaluated by quantitative fluorescence cytometry are detected on B-lymphocytes, CD 34+ cells and tumor cells of patients with chronic B-cell lymphoproliferative diseases.
Klabusay M; Sukova V; Coupek P; Brychtova Y; Mayer J
Cytometry B Clin Cytom; 2007 Sep; 72(5):363-70. PubMed ID: 17428002
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic targeting of CD19 in hematological malignancies: past, present, future and beyond.
Katz BZ; Herishanu Y
Leuk Lymphoma; 2014 May; 55(5):999-1006. PubMed ID: 23885836
[TBL] [Abstract][Full Text] [Related]
40. Expression of an anti-CD33 single-chain antibody by Pichia pastoris.
Emberson LM; Trivett AJ; Blower PJ; Nicholls PJ
J Immunol Methods; 2005 Oct; 305(2):135-51. PubMed ID: 16139294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
